Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. First-in-human phase I study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results